Kristen Hege

Kristen Hege serves as a member of the Board of Directors for Kelonia Therapeutics, Adaptimmune, and Mersana Therapeutics. Kristen holds the position of Senior Vice President of Early Clinical Development in Hematology/Oncology and Cell Therapy at Bristol-Myers Squibb. Additionally, Kristen is a Clinical Professor of Medicine in Hematology/Oncology at the University of California, San Francisco - School of Medicine. Education includes a Fellowship in Hematology-Oncology from the University of California, San Francisco - School of Medicine (1992-1995) and an Internship and Residency in Internal Medicine from Harvard Medical School (1989-1992).